The Situation
Our client, a clinical-stage biotech focused on the development of novel small-molecule drugs that target key mechanisms of cancer development with an asset for a rare oncology indication, was preparing for market access and commercialization in Europe.
The client has done preliminary work on TPP, value proposition, place in therapy and revenue potential scenarios. They needed to develop a solid strategy to support the launch of their rare oncology indication asset.
The Solution
Our European experts worked with the client to conduct a full European Commercial Readiness Opportunity Assessment to understand:
EU Market Prioritization
- Directional assessment of potential volumes and pricing
- Country clustering and sequencing
- Execution plan development at the country level
Pricing & Access Strategy
- Development and testing of a payer value proposition
- Directional price corridor setting
- Identification of most suitable access routes
The Results
Our team of European experts provided a full 140+ page report complete with a landscape assessment, payer value proposition and key findings.
The report included the following outcomes:
- Regulatory strategy
- Investment requirements
- Supply chain and distribution strategy
- Analogue price analysis
- Patient and value opportunity assessment
- Patient engagement strategy
- Early access/compassionate use scheme assessment
- Access and HEOR landscape assessment and requirements
- Launch sequence optimization strategy